{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:10:30Z","timestamp":1784049030221,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the promise of immune checkpoint blockade (ICB), only a minority of non-small-cell lung cancer (NSCLC) patients achieve long-term benefits. In this study, we present a single-cell spatial transcriptomic landscape of NSCLC, revealing a previously uncharacterized link between elevated glutathione peroxidase 8 (Gpx8) and resistance to PD-1 blockade. Through CyTOF, CODEX, and ATAC-sequencing analyses, we demonstrate that Gpx8 knockout in both immunocompetent and humanized mouse models suppress tumor growth. This suppression is accompanied by increased infiltration of antitumor T lymphocytes, reduced enrichment of pro-tumorigenic myeloid cells, and the formation of tertiary lymphoid structures (TLS). Mechanistically, Gpx8 inhibits the activity of the RNA-binding protein Celf1(CUGBP Elav-like family member 1) through disulfide bonding between cysteine 79 of Gpx8 and cysteine 177 of Celf1. This interaction stabilizes CCAAT-enhancer-binding protein \u03b2 (C\/EBP\u03b2) mRNA, promotes CSF1 secretion, and drives the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment. Notably, resistance to anti-PD-1 treatment in Gpx8-expressing NSCLCs can be overcome through enforced expression of Celf1, CSF1R blockade, or a mimic peptide designed to disrupt the Gpx8-Celf1 interaction. Furthermore, anti-PD-1 or rCSF1 treatment activates C\/EBP\u03b2 and upregulates Gpx8 transcription, establishing a Gpx8-C\/EBP\u03b2-CSF1 feedback loop that contributes to immune evasion. These findings provide new insights into the role of Gpx8 in modulating the tumor microenvironment and offer a potential framework for enhancing the sensitivity of NSCLC to PD-1 blockade therapy.<\/jats:p>","DOI":"10.1038\/s41418-026-01818-2","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:34:01Z","timestamp":1784046841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting of Gpx8-CSF1 axis resets the immune milieu of lung tumor and overcomes resistance to anti-PD-1 therapy"],"prefix":"10.1038","author":[{"given":"Heng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-7977","authenticated-orcid":false,"given":"Meng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-1745","authenticated-orcid":false,"given":"Huadong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-4433","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5086-5334","authenticated-orcid":false,"given":"Zhi-Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-4180","authenticated-orcid":false,"given":"Xing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8293-8133","authenticated-orcid":false,"given":"Wen\u2011Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1818_CR1","doi-asserted-by":"crossref","unstructured":"Sidaway P. Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC. Nat Rev Clin Oncol. 2024;566:21.","DOI":"10.1038\/s41571-024-00915-w"},{"key":"1818_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LE Hendriks","year":"2024","unstructured":"Hendriks LE, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Prim. 2024;10:71.","journal-title":"Nat Rev Dis Prim"},{"key":"1818_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi Z-D, Wei L-Y, Dong Y, Ma Y-Y, Wang W, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updates. 2023;66:100907.","journal-title":"Drug Resist Updates"},{"key":"1818_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409356","volume":"11","author":"W Hu","year":"2024","unstructured":"Hu W, Bian Y, Ji H. TIL therapy in lung cancer: current progress and perspectives. Adv Sci. 2024;11:2409356.","journal-title":"Adv Sci"},{"key":"1818_CR5","doi-asserted-by":"crossref","unstructured":"Sicard G, Protzenko D, Giacometti S, Barl\u00e9si F, Ciccolini J, Fanciullino R. Overcoming immuno-resistance by rescheduling anti-VEGF\/cytotoxics\/anti-PD-1 combination in lung cancer model. Cancer Drug Resist. 2024;7:10.","DOI":"10.20517\/cdr.2023.146"},{"key":"1818_CR6","doi-asserted-by":"crossref","unstructured":"Wang H, Wang X, Zhang X, Xu W. The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resist Updates. 2024;73:101041.","DOI":"10.1016\/j.drup.2023.101041"},{"key":"1818_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21:610\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"1818_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/curroncol31010001","volume":"31","author":"CH Coschi","year":"2023","unstructured":"Coschi CH, Juergens RA. Overcoming resistance mechanisms to immune checkpoint inhibitors: leveraging the anti-tumor immune response. Curr Oncol. 2023;31:1\u201323.","journal-title":"Curr Oncol"},{"key":"1818_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s10238-022-00946-6","volume":"23","author":"G Bronte","year":"2023","unstructured":"Bronte G, Calabr\u00f2 L, Olivieri F, Procopio AD, Crin\u00f2 L. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis. Clin Exp Med. 2023;23:1551\u201361.","journal-title":"Clin Exp Med"},{"key":"1818_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215924","volume":"15","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen G, Feng X, Song H, Meng L, Fu Y, et al. Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression. EMBO Mol Med. 2023;15:e15924.","journal-title":"EMBO Mol Med"},{"key":"1818_CR11","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/j.cllc.2020.10.018","volume":"22","author":"DH Owen","year":"2021","unstructured":"Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, et al. Deep and durable response to nivolumab and temozolomide in small-cell lung cancer associated with an early decrease in myeloid-derived suppressor cells. Clin Lung Cancer. 2021;22:e487\u2013e97.","journal-title":"Clin Lung Cancer"},{"key":"1818_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1147414","volume":"14","author":"J Pei","year":"2023","unstructured":"Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol. 2023;14:1147414.","journal-title":"Front Pharmacol"},{"key":"1818_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.freeradbiomed.2022.05.003","volume":"187","author":"L Floh\u00e9","year":"2022","unstructured":"Floh\u00e9 L, Toppo S, Orian L. The glutathione peroxidase family: discoveries and mechanism. Free Radic Biol Med. 2022;187:113\u201322.","journal-title":"Free Radic Biol Med"},{"key":"1818_CR14","doi-asserted-by":"publisher","first-page":"e39815","DOI":"10.1097\/MD.0000000000039815","volume":"104","author":"Y-W Zou","year":"2025","unstructured":"Zou Y-W, Cheng Y, Liu Z-L, Wang H-T. GPX8 as a potential prognostic marker in gastric and colorectal cancer. Medicine. 2025;104:e39815.","journal-title":"Medicine"},{"key":"1818_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.152","volume":"3","author":"YL Xu","year":"2022","unstructured":"Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, et al. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. MedComm. 2022;3:e152.","journal-title":"MedComm"},{"key":"1818_CR16","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1111\/1759-7714.13671","volume":"11","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu Y, Guo Y, Zhao Q. GPX8 promotes migration and invasion by regulating epithelial characteristics in non-small cell lung cancer. Thorac Cancer. 2020;11:3299\u2013308.","journal-title":"Thorac Cancer"},{"key":"1818_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbae134","volume":"4","author":"J Hastings","year":"2024","unstructured":"Hastings J, Lee D, O\u2019Connell MJ. Batch-effect correction in single-cell RNA sequencing data using JIVE. Bioinforma Adv. 2024;4:vbae134.","journal-title":"Bioinforma Adv"},{"key":"1818_CR18","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.3390\/ijms25115617","volume":"25","author":"AT Abdallah","year":"2024","unstructured":"Abdallah AT, Konermann A. Unraveling divergent transcriptomic profiles: a comparative single-cell RNA sequencing study of epithelium, gingiva, and periodontal ligament tissues. Int J Mol Sci. 2024;25:5617.","journal-title":"Int J Mol Sci"},{"key":"1818_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani M, Xue H, Park JS, Dentro SC, Seferbekova Z, Tessier J, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024;15:4388.","journal-title":"Nat Commun"},{"key":"1818_CR20","doi-asserted-by":"crossref","unstructured":"Kim KH, Kim SJ, Eccles JD, Ascoli C, Park GY. Tumor immunogenicity regulates host immune responses, and conventional dendritic cell type 2 uptakes the majority of tumor antigens in an orthotopic lung cancer model. Cancer Immunol Immunother. 2024;73:237.","DOI":"10.1007\/s00262-024-03828-w"},{"key":"1818_CR21","first-page":"397","volume":"5","author":"C-L Lee","year":"2012","unstructured":"Lee C-L, Moding EJ, Huang X, Li Y, Woodlief LZ, Rodrigues RC, et al. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Dis Models Mech. 2012;5:397\u2013402.","journal-title":"Dis Models Mech"},{"key":"1818_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang N, Bevan MJ. CD8+ T cells: foot soldiers of the immune system. Immunity. 2011;35:161\u20138.","journal-title":"Immunity"},{"key":"1818_CR23","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1158\/0008-5472.CAN-23-2716","volume":"84","author":"D An","year":"2024","unstructured":"An D, Chen G, Cheng W-Y, Mohrs K, Adler C, Gupta NT, et al. LT\u03b2R agonism promotes antitumor immune responses via modulation of the tumor microenvironment. Cancer Res. 2024;84:3984\u20134001.","journal-title":"Cancer Res"},{"key":"1818_CR24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","volume":"5","author":"K Nutsch","year":"2024","unstructured":"Nutsch K, Banta KL, Wu TD, Tran CW, Mittman S, Duong E, et al. TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation. Nat Cancer. 2024;5:1834\u201351.","journal-title":"Nat Cancer"},{"key":"1818_CR25","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.4049\/jimmunol.2400119","volume":"213","author":"HM Nieves-Rosado","year":"2024","unstructured":"Nieves-Rosado HM, Banerjee H, Gocher-Demske A, Manandhar P, Mehta I, Ezenwa O, et al. Tim-3 is required for regulatory T cell\u2013mediated promotion of T cell exhaustion and viral persistence during chronic lymphocytic choriomeningitis virus infection. J Immunol. 2024;213:1488\u201398.","journal-title":"J Immunol"},{"key":"1818_CR26","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","volume":"72","author":"W Peng","year":"2012","unstructured":"Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res. 2012;72:5209\u201318.","journal-title":"Cancer Res"},{"key":"1818_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112949","volume":"142","author":"S Rajkumari","year":"2024","unstructured":"Rajkumari S, Singh J, Agrawal U, Agrawal S. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives. Int Immunopharmacol. 2024;142:112949.","journal-title":"Int Immunopharmacol"},{"key":"1818_CR28","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.1073\/pnas.0711961105","volume":"105","author":"R Feng","year":"2008","unstructured":"Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, Stanley ER, et al. PU. 1 and C\/EBP\u03b1\/\u03b2 convert fibroblasts into macrophage-like cells. Proc Natl Acad Sci USA. 2008;105:6057\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1818_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/hmg\/ddt419","volume":"23","author":"YK Kim","year":"2014","unstructured":"Kim YK, Mandal M, Yadava RS, Paillard L, Mahadevan MS. Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity. Hum Mol Genet. 2014;23:293\u2013302.","journal-title":"Hum Mol Genet"},{"key":"1818_CR30","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809386","volume":"12","author":"JL Hsu","year":"2020","unstructured":"Hsu JL, Chou JW, Chen TF, Hsu JT, Su FY, Lan JL, et al. Glutathione peroxidase 8 negatively regulates caspase-4\/11 to protect against colitis. EMBO Mol Med. 2020;12:e9386.","journal-title":"EMBO Mol Med"},{"key":"1818_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994333","volume":"12","author":"P Kanikarla Marie","year":"2022","unstructured":"Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, et al. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol. 2022;12:994333.","journal-title":"Front Oncol"},{"key":"1818_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260169","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zheng D, Lin Z, Zhang C, Wei C, Deng X, et al. GPX8 regulates pan-apoptosis in gliomas to promote microglial migration and mediate immunotherapy responses. Front Immunol. 2023;14:1260169.","journal-title":"Front Immunol"},{"key":"1818_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010833","volume":"13","author":"SL Topalian","year":"2025","unstructured":"Topalian SL, Pardoll DM. Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care. J Immunother Cancer. 2025;13:e010833.","journal-title":"J Immunother Cancer"},{"key":"1818_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol cancer. 2022;21:184.","journal-title":"Mol cancer"},{"key":"1818_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.898204","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Jiang X, Guan M, Zhang Y, Cao Y, Zhang L. The overexpression of GPX8 is correlated with poor prognosis in GBM patients. Front Genet. 2022;13:898204.","journal-title":"Front Genet"},{"key":"1818_CR36","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","volume":"34","author":"S Gettinger","year":"2016","unstructured":"Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non\u2013small-cell lung cancer. J Clin Oncol. 2016;34:2980\u20137.","journal-title":"J Clin Oncol"},{"key":"1818_CR37","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1818_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114044","volume":"180","author":"M Zorko","year":"2022","unstructured":"Zorko M, Jones S, Langel \u00dc. Cell-penetrating peptides in protein mimicry and cancer therapeutics. Adv drug Deliv Rev. 2022;180:114044.","journal-title":"Adv drug Deliv Rev"},{"key":"1818_CR39","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.3390\/cells10112908","volume":"10","author":"CM Li","year":"2021","unstructured":"Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, et al. Novel peptide therapeutic approaches for cancer treatment. Cells. 2021;10:2908.","journal-title":"Cells"},{"key":"1818_CR40","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/ijms23031445","volume":"23","author":"M Akbarian","year":"2022","unstructured":"Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive peptides: synthesis, sources, applications, and proposed mechanisms of action. Int J Mol Sci. 2022;23:1445.","journal-title":"Int J Mol Sci"},{"key":"1818_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.","journal-title":"Nat Commun"},{"key":"1818_CR42","doi-asserted-by":"publisher","first-page":"e1007278","DOI":"10.1371\/journal.pgen.1007278","volume":"14","author":"AD Siddam","year":"2018","unstructured":"Siddam AD, Gautier-Courteille C, Perez-Campos L, Anand D, Kakrana A, Dang CA, et al. The RNA-binding protein Celf1 post-transcriptionally regulates p27Kip1 and Dnase2b to control fiber cell nuclear degradation in lens development. PLoS Genet. 2018;14:e1007278.","journal-title":"PLoS Genet"},{"key":"1818_CR43","doi-asserted-by":"publisher","DOI":"10.4155\/fdd-2022-0005","volume":"4","author":"C Lamers","year":"2022","unstructured":"Lamers C. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discov. 2022;4:FDD75.","journal-title":"Future Drug Discov"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01818-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:34:03Z","timestamp":1784046843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01818-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":43,"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01818-2","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The other authors declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We gratefully thank all the patients, their families and caregivers from each site who participated in and promoted this study.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study included 280 NSCLC patients who underwent surgical operation between 2020 and 2024 at the Affiliated Chest Hospital of Shanghai Jiaotong University and Wuhan University Renmin Hospital. Human tissue sample collection was approved by the Ethics Committee of Shanghai Chest Hospital. The informed consent was signed by each patient. The experimental protocols involving human samples conformed to the Helsinki Declaration and were permitted by the Institutional Review Board of Wuhan University Renmin Hospital and Shanghai Chest Hospital.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}